FDA approves first vaccine for RSV, a moment six decades in the ... - CNN
WEBMay 3, 2023 · CNN — After a 60-year scientific quest, the world has its first vaccine to protect against respiratory syncytial virus, or RSV – and more are on the way. On Wednesday, the US Food and Drug...
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
WEBMay 4, 2023 · Arexvy is the first RSV vaccine approved by the FDA for the prevention of lower respiratory tract disease in individuals 60 years of age and older. RSV is a highly contagious virus that can cause...
FDA approves RSV vaccine for adults ages 60 and up - NBC News
WEBMay 3, 2023 · By Aria Bendix. The Food and Drug Administration on Wednesday approved the world's first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK. The milestone was decades...
US approves 1st vaccine for RSV after decades of attempts
WEBMay 3, 2023 · The U.S. has approved the first vaccine for RSV, shots to protect older adults. The respiratory virus filled hospitals with wheezing babies last fall but also endangers seniors.
FDA Approves Pfizer’s RSV Vaccine for Adults 60 and Older - The …
WEBMay 31, 2023 · The Food and Drug Administration on Wednesday approved Pfizer’s vaccine against the respiratory syncytial virus, or R.S.V., for adults age 60 and older, the second approval granted for shots...
FDA approves first vaccine for RSV after decades of attempts
WEBMay 3, 2023 · WASHINGTON — The U.S. approved the first vaccine for RSV on Wednesday, allowing the sale of shots to protect older adults from a respiratory virus that’s most notorious for attacking babies but...
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older …
WEBDec 13, 2023 · Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality among older adults. An mRNA-based RSV vaccine, mRNA-1345, encoding the stabilized RSV prefusion F glycoprotein,...
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ...
WEBApr 9, 2024 · ABRYSVO is a bivalent vaccine that protects against respiratory syncytial virus (RSV), a common cause of lower respiratory tract disease (LRTD) in high-risk adults. Pfizer announced positive results from a Phase 3 study of ABRYSVO in adults 18 to 59 with chronic conditions or immunocompromised.
Vaccines could offer fresh hope against respiratory syncytial virus
WEBSep 27, 2023 · After decades of failure, several vaccines and antiviral antibodies for respiratory syncytial virus (RSV) are showing promise in clinical trials. But access and equity issues could limit...
‘A good day’: FDA approves world’s first RSV vaccine - Nature
WEBMay 3, 2023 · The US Food and Drug Administration (FDA) has approved GSK’s vaccine against respiratory syncytial virus (RSV) for use in people aged 60 years and older. This is the first RSV vaccine to gain...